Reboxetine (Axsome Therapeutics)

瑞波西汀

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameReboxetine (Axsome Therapeutics)
Drug Alias NameAXS-12
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNorepinephrine reuptake inhibitors
TargetsNorepinephrine transporter
Therapy Area/IndicationsCataplexyNarcolepsyDisorders of Excessive Somnolence +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAxsome Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFlinders UniversityAxsome Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCataplexyNarcolepsyDisorders of Excessive Somnolence +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A